CTLA4 and cancer: With the introduction and the success of immune checkpoint inhibitors in cancer treatments (anti-PD1, anti-PDL1, anti-CTLA4) [for review, see (1)], most of the scientific interest was focused on T lymphocytes due to the ability of certain T cell subsets to clear pathogens and cancer cells.